Avecho Biotechnology Ltd has released a press release.
AVE signs development agreement with Perrigo
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- September 2022 Quarterly Activities Report & Appendix 4C
- Increased CBD absorption in dogs vs commercial comparator
- June 2022 Quarterly Activities Report & Appendix 4C
- Security Class Reinstatement to Quotation- AVEO
- Update on Listed Options and Federal Court Application
Later from Avecho Biotechnology
- Avecho receives ethics approval for Phase III CBD trial
- Athenex submits Avechos phytonadione to FDA pre-IND
- December 2022 Quarterly Activities Report & Appendix 4C
- Clinical CBD program expands with the Lambert Initiative
- Entitlement Offer to raise $11m for Phase 3 clinical trial
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology